Meiling Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Meiling Chen has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Bin Zhang
Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, City of Hope Medical Center, Duarte, USA
4 shared publications - Chao Shen
Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA
4 shared publications - Chengwan Zhang
Department of Central Laboratory, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
4 shared publications - Chuan He
Department of Chemistry, University of Chicago, Chicago, USA
4 shared publications - Diyuan Xue
Department of Systems Biology and Center for RNA Biology and Therapeutics, Beckman Research Institute of City of Hope, Monrovia, California
4 shared publications - Dong Wu
Department of Systems Biology and Center for RNA Biology and Therapeutics, Beckman Research Institute of City of Hope, Monrovia, California
4 shared publications
Latest Publications
- 29 July 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (10) , e1218-e1228.e3
Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
- 29 July 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (10) , e1218-e1228.e3
Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S3 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Table S1: Effects of ALKBH1 KD on f5C34 in mitochondrial tRNA-Met Supplementary Table S2: Genetic background of the AML patient samples. Supplementary Table S3: List of oligonucleotide sequences
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S3 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Table S1: Effects of ALKBH1 KD on f5C34 in mitochondrial tRNA-Met Supplementary Table S2: Genetic background of the AML patient samples. Supplementary Table S3: List of oligonucleotide sequences
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Proteomics Data 1 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Quantitative proteomics after ALKBH1 knockdown in MOLM13 cells.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Proteomics Data 1 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Quantitative proteomics after ALKBH1 knockdown in MOLM13 cells.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Figure S1. ALKBH1 is required for human AML cell survival/growth in vitro and human AML progression in vivo. Supplementary Figure S2. ALKBH1 is required for leukemic cell transformation, LSC/LIC self-renewal and AML maintenance. Supplementary Figure S3. ALKBH1 is dispensable for normal hematopoiesis. Supplementary Figure S4. ALKBH1 is required for mitochondrial functions in AML cells. Supplementary Figure S5. ALKBH1 specifically catalyzes the conversion of m5C/m5Cm to f5C in tRNAs and is crutial for protein translation in AML. Supplementary Figure S6. WDR43 is a direct target of ALKBH1 through tRNA f5C-mediaed codon biased translation and phenocopies the functions of ALKBH1 in AML. Supplementary Figure S7. Discovery of the ALKBH1/WDR43/BCL2 axis and the synergistic effect of targeting ALKBH1/WDR43/BCL2 axis together with venetoclax in treating AML.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Figure S1. ALKBH1 is required for human AML cell survival/growth in vitro and human AML progression in vivo. Supplementary Figure S2. ALKBH1 is required for leukemic cell transformation, LSC/LIC self-renewal and AML maintenance. Supplementary Figure S3. ALKBH1 is dispensable for normal hematopoiesis. Supplementary Figure S4. ALKBH1 is required for mitochondrial functions in AML cells. Supplementary Figure S5. ALKBH1 specifically catalyzes the conversion of m5C/m5Cm to f5C in tRNAs and is crutial for protein translation in AML. Supplementary Figure S6. WDR43 is a direct target of ALKBH1 through tRNA f5C-mediaed codon biased translation and phenocopies the functions of ALKBH1 in AML. Supplementary Figure S7. Discovery of the ALKBH1/WDR43/BCL2 axis and the synergistic effect of targeting ALKBH1/WDR43/BCL2 axis together with venetoclax in treating AML.
- 4 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (11) , 2298-2325
ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Cancer cells utilize codon-biased translation to fuel tumorigenesis and drug resistance; however, underlying mechanisms remain poorly understood. In this study, we show that ALKBH1 is overexpressed in acute myeloid leukemia (AML) and essential for leukemia stem cell/leukemia-initiating cell self-renewal and AML development/maintenance but dispensable for normal hematopoiesis. ALKBH1 enhances mitochondrial assembly/function and oxidative phosphorylation, crucial for AML survival/proliferation and resistance to venetoclax, a potent BCL2 inhibitor and widely used first-line targeted therapy for AML in the clinic. Mechanistically, ALKBH1 catalyzes 5-formylcytosine at tRNA wobble positions, reprograming decoding and facilitating codon-biased translation, a mechanism we term “epitranslatomic Midas touch,” which in turn drives leukemogenesis and drug resistance by promoting the synthesis of key oncogenic proteins like WDR43. Targeting ALKBH1, particularly together with venetoclax, exhibited potent antileukemia efficacy in preclinical models with favorable safety profiles. Collectively, our findings elucidate ALKBH1’s pivotal role in codon-biased translation and tumorigenesis and propose a novel therapeutic strategy for cancer treatment. Significance: This study uncovers that ALKBH1-driven tRNA-decoding reprogramming and codon-biased translation, termed “epitranslatomic Midas touch,” is crucial for leukemogenesis, leukemia stem cell/leukemia-initiating cell self-renewal, mitochondria structure/function, and resistance to venetoclax. Targeting ALKBH1, especially in combination with venetoclax, offers a promising therapeutic strategy to combat drug resistance in AML and potentially other ALKBH1-overexpressing cancers.
- 4 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (11) , 2298-2325
ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Cancer cells utilize codon-biased translation to fuel tumorigenesis and drug resistance; however, underlying mechanisms remain poorly understood. In this study, we show that ALKBH1 is overexpressed in acute myeloid leukemia (AML) and essential for leukemia stem cell/leukemia-initiating cell self-renewal and AML development/maintenance but dispensable for normal hematopoiesis. ALKBH1 enhances mitochondrial assembly/function and oxidative phosphorylation, crucial for AML survival/proliferation and resistance to venetoclax, a potent BCL2 inhibitor and widely used first-line targeted therapy for AML in the clinic. Mechanistically, ALKBH1 catalyzes 5-formylcytosine at tRNA wobble positions, reprograming decoding and facilitating codon-biased translation, a mechanism we term “epitranslatomic Midas touch,” which in turn drives leukemogenesis and drug resistance by promoting the synthesis of key oncogenic proteins like WDR43. Targeting ALKBH1, particularly together with venetoclax, exhibited potent antileukemia efficacy in preclinical models with favorable safety profiles. Collectively, our findings elucidate ALKBH1’s pivotal role in codon-biased translation and tumorigenesis and propose a novel therapeutic strategy for cancer treatment. Significance: This study uncovers that ALKBH1-driven tRNA-decoding reprogramming and codon-biased translation, termed “epitranslatomic Midas touch,” is crucial for leukemogenesis, leukemia stem cell/leukemia-initiating cell self-renewal, mitochondria structure/function, and resistance to venetoclax. Targeting ALKBH1, especially in combination with venetoclax, offers a promising therapeutic strategy to combat drug resistance in AML and potentially other ALKBH1-overexpressing cancers.
- 31 July 2018
- Published by Wiley in Macromolecular Materials and Engineering
- Vol. 303 (10)
“Zylon” Aerogels
Ultralight materials with challenging combinations of properties such as high mechanical stiffness at low density, high thermal and environmental stabilities, are hard to achieve. Here, poly(p‐phenylene benzobisoxazole) (PBO) nanofibers derived from “super” fibers (Zylon) are assembled into a robust 3D porous structure, forming aerogels with integrated performance surpassing previously existing polymeric aerogels. “Zylon” aerogel has a specific compressive modulus of 72 MPa g−1 cm3 at a density as low as 32 mg cm−3, low thermal conductivity (0.045 W m−1 K−1) at 500 °C, and an intrinsic moisture resistance. PBO nanofibers also empower “Zylon” aerogels with high thermal stability up to 692 °C, a near‐zero thermal expansion coefficient, and a superior fire‐retardant capability. These attractive multiparameter properties make “Zylon” aerogels highly competitive lightweight construction structures. The use of polymeric assembly units with intrinsic demanding characteristics represents an essential pathway toward rationalizing the design of high‐performance aerogels.
- 31 July 2018
- Published by Wiley in Macromolecular Materials and Engineering
- Vol. 303 (10)
“Zylon” Aerogels
Ultralight materials with challenging combinations of properties such as high mechanical stiffness at low density, high thermal and environmental stabilities, are hard to achieve. Here, poly(p‐phenylene benzobisoxazole) (PBO) nanofibers derived from “super” fibers (Zylon) are assembled into a robust 3D porous structure, forming aerogels with integrated performance surpassing previously existing polymeric aerogels. “Zylon” aerogel has a specific compressive modulus of 72 MPa g−1 cm3 at a density as low as 32 mg cm−3, low thermal conductivity (0.045 W m−1 K−1) at 500 °C, and an intrinsic moisture resistance. PBO nanofibers also empower “Zylon” aerogels with high thermal stability up to 692 °C, a near‐zero thermal expansion coefficient, and a superior fire‐retardant capability. These attractive multiparameter properties make “Zylon” aerogels highly competitive lightweight construction structures. The use of polymeric assembly units with intrinsic demanding characteristics represents an essential pathway toward rationalizing the design of high‐performance aerogels.